# Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

> **NCT01824823** · PHASE2 · TERMINATED · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 3 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** afatinib
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT01824823
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06-30
- **Primary completion:** 2015-12-13
- **Final completion:** 2020-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2023-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01824823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01824823, "Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01824823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*